M
MapLight Therapeutics
Precision neuroscience developing targeted therapies for serious brain disorders
About MapLight Therapeutics
MapLightRx is a pioneering startup in the healthcare sector, specifically focusing on brain disorders such as Autism, Parkinson's, and Schizophrenia. The company is on a mission to revolutionize the current treatment landscape, which is characterized by limited options, moderate effectiveness, and significant side effects. MapLightRx aims to provide more targeted and effective treatments for patients, moving away from the traditional approach of using generalized therapeutics.
Read full description
The company operates in the medical research and development market, serving patients suffering from brain disorders. Its business model revolves around the development of a unique discovery platform that combines advanced technologies to identify and target the individual circuits that malfunction in brain disorders. This platform is built on proprietary, patented innovations such as optogenetics, STARmap, and transcriptomics.
MapLightRx's revenue generation strategy is based on the development and commercialization of safe, effective therapeutics for brain disorders. The company has a strong pipeline of potential treatments, with two lead compounds already in clinical trials. These treatments show promise for multiple indications and disorders, including social deficits related to Autism and unwanted movements related to Parkinson's disease.
In summary, MapLightRx is a promising startup in the healthcare sector, leveraging cutting-edge technologies to develop targeted treatments for brain disorders. Its unique approach and strong pipeline of potential treatments position it well for future growth in the medical research and development market.
At a glance
- Founded
- 2018
- Headquarters
- Redwood City, United States
- Listing
- IPO 2025
- Sector
- Biotech & Life Sciences
- Power Law
- Unicorn$1–10B valuation tier
Latest news
Press, funding announcements and product moves mentioning MapLight Therapeutics.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Michael J. Fox Foundation for Parkinson's Research
Series B and later9 investors entered at this stage
Novo Holdings
5AM Ventures- CICowen Healthcare Investments
Goldman Sachs Asset Management
Forbion Capital Partners
T. Rowe Price
Blue Owl Capital
Sanofi- ACAvego Bioscience Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
across markets
Patents
7 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Market sentiment
An AI-synthesised read of the highest-engagement posts about MapLight Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See MapLight Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.